scispace - formally typeset
L

Louis P. Garrison

Researcher at University of Washington

Publications -  228
Citations -  6705

Louis P. Garrison is an academic researcher from University of Washington. The author has contributed to research in topics: Cost effectiveness & Health care. The author has an hindex of 41, co-authored 210 publications receiving 5607 citations. Previous affiliations of Louis P. Garrison include Hoffmann-La Roche & Mercer University.

Papers
More filters
Journal ArticleDOI

Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya

TL;DR: Preventative cryotherapy was the least expensive strategy and resulted in highest projected life expectancy, while VIA was most cost-effective unless HPV screening could be reduced to a single visit.
Journal ArticleDOI

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer.

TL;DR: In this paper, the authors provide a perspective on the limitations, benefits, and potential enhancement of this approach to support value-based medicine and provide an analysis of the potential benefits and potential enhancements.
Journal ArticleDOI

Using Certification to Promote Uptake of Real-World Evidence by Payers

TL;DR: A process by which an independent body would certify observational studies as generating valid and unbiased estimates of the effectiveness of the intervention under consideration is proposed, suggesting that the rigor and transparency that will be required with such a process, and the unassailable evidence that it will produce, will be valuable to decision makers.
Journal ArticleDOI

Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007.

TL;DR: Health‐outcomes modeling suggested that the use of rosiglitazone as monotherapy was not initially warranted, given the uncertainty with regard to benefit, and a mathematical diabetes model was adapted to estimate NB and uncertainty of diabetes monotherapy.
Journal ArticleDOI

Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic.

TL;DR: In this paper, a virtual expert panel that met to attempt a consensus on how existing principles of economic evaluation should be applied to therapeutics that emerge in a pandemic setting, with specific focus on severe hospitalised cases of the coronavirus disease 2019 (COVID-19) pandemic.